Search Results - "Burhenne J"

Polar photodegradation products of quinolones determined by HPLC/MS/MS.

Authors: Burhenne, J. Ludwig, M. Spiteller, M.

Source: Chemosphere. Mar1999, Vol. 38 Issue 6, p1279. 8p.

Subjects: Quinolone antibacterial agents, High performance liquid chromatography

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

The role of biotic and abiotic degradation processes during the formation of typical toxaphene peak patterns in aquatic biota

Authors: Angerhofer, D. Burhenne, J. Parlar, H. et al.

Source: Chemosphere. Aug1999, Vol. 39 Issue 4, p563. 0p.

Subjects: Bioaccumulation, Ecology

Polar photodegradation products of quinolones determined by HPLC/MS/MS

Authors: Ludwig, M. Burhenne, J. Spiteller, M.

Source: Chemosphere. Jun1999, Vol. 38 Issue 14, p1279. 0p.

Subjects: Atmospheric chemistry, High performance liquid chromatography, Mass spectrometry

Structure elucidation of the three most important toxaphene congeners by x-ray analysis

Authors: Hainzl, D. Burhenne, J. Parlar, H. et al.

Source: Chemosphere. Jun1994, Vol. 28 Issue 12, p2067. 0p.

Subjects: X-rays

Theoretical consideration of the structural variety in the toxaphenemixture taking into account recent experimental results

Authors: Parlar, H. Burhenne, J. Haizl, D.

Source: Chemosphere. Jan1994, Vol. 28 Issue 2, p245. 0p.

Subjects: Pesticides, Toxaphene

Isolation and characterization of environmental relevant single toxaphene components

Authors: Parlar, H. Burhenne, J. Hainzl, D.

Source: Chemosphere. Nov1993, Vol. 27 Issue 10, p1857. 0p.

Subjects: Spectrum analysis, Toxaphene

138 A NOVEL BILE SALT-PHOSPHOLIPID CONJUGATE URSODEOXYCHOLYL-LYSOPHOSPHATIDYLETHANOLAMIDE AS A HEPATIC CYTOPROTECTIVE AGENT

Authors: Chamulitrat, W. Burhenne, J. Rehlen, T. et al.

Source: Journal of Hepatology. May2008 Supplement 2, Vol. 48, pS59-S59. 1p.

[764] CYTOPROTECTIVE FUNCTIONS OF A BILE SALT-PHOSPHOLIPID CONJUGATE LYSOPHOSPHATIDYL-ETHANOLAMINO-URSODEOXYCHOLATE: IMPLICATIONS FOR TREATMENT OF LIVER DISEASES

Authors: Chamulitrat, W. Burhenne, J. Stremmel, W.

Source: Journal of Hepatology. Apr2007, Vol. 46, pS287-S287. 1p.

Sildenafil Plasma Concentrations during Routine Treatment of Children with Pulmonary Arterial Hypertension.

Authors: Grommes, S. Ziesenitz, V.C. Burhenne, J. et al.

Source: Thoracic & Cardiovascular Surgeon, Supplement. 2018 Supplement1, Vol. 66, pS111-S138. 28p.

This result is not displayed to guests.
Login for full access.

Voriconazole-Induced QT Interval Prolongation and Ventricular Tachycardia: A Non--Concentration-Dependent Adverse Effect.

Authors: Alkan, Y. Haefeli, W. E. Burhenne, J. et al.

Source: Clinical Infectious Diseases. 9/15/2004, Vol. 39 Issue 6, pe49-e52. 4p.

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.

Authors: Habtewold, A Amogne, W Makonnen, E et al.

Source: Pharmacogenomics Journal. Dec2013, Vol. 13 Issue 6, p484-489. 6p.

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.

Authors: Yimer, G Amogne, W Habtewold, A et al.

Source: Pharmacogenomics Journal. Dec2012, Vol. 12 Issue 6, p499-506. 8p. 3 Charts, 2 Graphs.

Higher chlorzoxazone clearance in obese children compared with nonobese peers.

Authors: Gade, C. Dalhoff, K. Petersen, T. S. et al.

Source: British Journal of Clinical Pharmacology. Aug2018, Vol. 84 Issue 8, p1738-1747. 10p. 2 Charts, 6 Graphs.

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

Authors: Ngaimisi, E Minzi, O Mugusi, S et al.

Source: Journal of Antimicrobial Chemotherapy (JAC). Dec2014, Vol. 69 Issue 12, p3311-3319. 9p.

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat.

Authors: Röttgen H Theurer L Peccerella T et al.

Source: Oncology reports [Oncol Rep] 2026 Jan; Vol. 55 (1). Date of Electronic Publication: 2025 Nov 21.

Publication Type: Journal Article

Journal Info: Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE

Rifabutin boosts rifampicin accumulation in THP-1-derived M2 macrophages by inhibiting P-glycoprotein efflux activity.

Authors: Hamburg K Bay C Burhenne J et al.

Source: Archives of toxicology [Arch Toxicol] 2026 Jun; Vol. 100 (6), pp. 2535-2541. Date of Electronic Publication: 2026 Mar 10.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0738 (Electronic) Linking ISSN: 03405761 NLM ISO Abbreviation: Arch Toxicol Subsets: MEDLINE

A UPLC-MS/MS assay for the quantification of the novel viral helicase-primase drug candidate adibelivir (IM-250) in human specimen.

Authors: Bay C Bergamino M Sauter M et al.

Source: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2026 May 01; Vol. 1275, pp. 124995. Date of Electronic Publication: 2026 Feb 26.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101139554 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-376X (Electronic) Linking ISSN: 15700232 NLM ISO Abbreviation: J Chromatogr B Analyt Technol Biomed Life Sci Subsets: MEDLINE